grant
Imaging tumor-associated macrophages in head and neck squamous cell carcinoma using fluorine-19 MRI
Organization UNIVERSITY OF CALIFORNIA, SAN DIEGOLocation LA JOLLA, UNITED STATESPosted 1 May 2024Deadline 30 Apr 2029
NIHUS FederalResearch GrantFY2025AnimalsAntibodiesAntitumor ResponseArtificial BloodArtificial ErythrocytesAssayB7-H1BioassayBiodistributionBiological AssayBiological MarkersBiopsyBlood SubstitutesBlood monocyteCD152CD152 AntigenCD152 GeneCD274CD68 antigenCTLA 4CTLA-4 GeneCTLA4CTLA4 geneCTLA4-TMCancer ModelCancer PatientCancer TreatmentCancerModelCancersCd68Cell BodyCell Communication and SignalingCell SignalingCellsCheckpoint inhibitorClinicClinicalClinical ResearchClinical StudyClinical TrialsCollaborationsContracting OpportunitiesContractsCytotoxic T-Lymphocyte Protein 4Cytotoxic T-Lymphocyte-Associated Antigen 4Cytotoxic T-Lymphocyte-Associated Protein 4Cytotoxic T-Lymphocyte-Associated Serine Esterase-4DataDetectionDiagnosisDiagnosticDiseaseDisease ProgressionDisorderDrug KineticsEndocytosisErythrocyte SubstitutesExcipientsExclusionF elementFluorineFluorocarbonsFormulationFutureGeneralized GrowthGoalsGood Manufacturing ProcessGood manufacturing practiceGrowthHNSCCHead and Neck CancerHead and Neck CarcinomaHead and Neck Squamous Cell CarcinomaHistologicHistologicallyHumanImageImaging technologyImmuneImmune checkpoint inhibitorImmune mediated therapyImmunesImmunologically Directed TherapyImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapeutic agentImmunotherapyIn SituIn VitroInflammationInflammatoryInjectableIntracellular Communication and SignalingLabelLeadLesionMR ImagingMR TomographyMRIMRIsMacrophageMagnetic Resonance ImagingMalignant Head and Neck NeoplasmMalignant Neoplasm TherapyMalignant Neoplasm TreatmentMalignant NeoplasmsMalignant TumorManufacturerMarrow monocyteMeasuresMedical Imaging, Magnetic Resonance / Nuclear Magnetic ResonanceModelingModern ManMorphologyMφNMR ImagingNMR TomographyNuclear Magnetic Resonance ImagingO elementO2 elementOilsOncologyOncology CancerOutcomeOxygenPD-1 antibodyPD-L1PD-L1 antibodyPD1 antibodyPDL-1PatientsPb elementPerfluorocarbonsPhagocytesPhagocytic CellPharmaceutical AgentPharmaceuticalsPharmacokineticsPharmacologic SubstancePharmacological SubstancePilot ProjectsPlayPredispositionPrognosisProgrammed Cell Death 1 Ligand 1Programmed Death Ligand 1Progression-Free SurvivalsRecurrenceRecurrentRed Cell SubstitutesReticuloendothelial SystemRoleSCCHNSafetySeveritiesSignal TransductionSignal Transduction SystemsSignalingSiteSolid NeoplasmSolid TumorSpecificityStaining methodStainsSusceptibilityT-CellsT-LymphocyteTechnologyTherapeuticTissue GrowthTracerTranslatingTumor VolumeTumor-associated macrophagesVesicleVisualizationWorkZeugmatographyaPD-1aPD-L1aPD-L1 antibodiesaPD1amebocyteangiogenesisanti programmed cell death 1anti programmed cell death ligand 1anti programmed cell death protein ligand 1anti-PD-(L)1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD-L1anti-PD-L1 antibodiesanti-PD-L1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-PDL-1anti-PDL1anti-PDL1 antibodiesanti-cancer therapyanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor responseantiPD-1antiPD-L1bio-markersbiologic markerbiological signal transductionbiomarkercancer imagingcancer microenvironmentcancer therapycancer-directed therapycheck point immunotherapycheck point inhibitor therapycheck point inhibitory therapycheck point therapycheckpoint immunotherapycheckpoint inhibitor therapycheckpoint inhibitory therapycheckpoint therapycolon cancer patientscolorectal cancer patientscytotoxic T-lymphocyte antigen 4densityexperiencefirst in manfirst-in-humangenotoxicitygood laboratory practicehead and neck squamous carcinomahead and neck squamous cell cancerhead/neck cancerheavy metal Pbheavy metal leadimagingimaging agentimaging probeimaging studyimmune check pointimmune check point inhibitorimmune check point therapyimmune checkpointimmune checkpoint therapyimmune drugsimmune suppressionimmune suppressive activityimmune suppressive functionimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapeuticsimmune-based therapiesimmune-based treatmentsimmunecheckpointimmuno therapyimmunologic therapeuticsimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunotherapeuticsimmunotherapy agentimproved outcomein vivoindividualized cancer therapyindividualized therapeuticintravenous administrationintravenous injectionmalignancymalignant head and neck tumormanufacturing organizationmonocytenano emulsionnanoemulsionneoplasm/cancernon-invasive imagingnon-invasive monitornoninvasive imagingnoninvasive monitornovelobjective response rateoncologic imagingoncology imagingontogenypatient populationpatient stratificationpersonalized cancer therapypersonalized cancer treatmentpersonalized therapeuticpharmaceuticalphase 1 trialphase I trialpilot studypre-clinicalpre-clinical imagingpre-clinical studypreclinicalpreclinical imagingpreclinical studyprognosticprogrammed cell death ligand 1programmed cell death protein ligand 1protein death-ligand 1responseresponse to therapyresponse to treatmentsocial rolestandard of carestratified patientsurfactanttherapeutic outcometherapeutic responsetherapeutic targettherapy outcometherapy responsethymus derived lymphocytetreatment responsetreatment responsivenesstumortumor imagingtumor microenvironmentuptakeαPD-1αPD-L1αPD-L1 antibodiesαPD1αPDL1
Description preview
In this project, we aim to translate a fluorine-19 (19F) MRI technology to visualize the tumor associated
macrophage (TAM) burden in patients with recurrent head and neck squamous cell carcinoma (HNSCC).
HNSCC is the sixth most common cancer worldwide. TAMs often comprise a significant volume fraction of tumor
mass, and a high TAM burden in the…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click